S961, a biosynthetic insulin receptor antagonist, downregulates insulin receptor expression & suppresses the growth of breast cancer cells

Background & objectives: Insulin resistance associated with hyperinsulinaemia and overexpression of insulin receptors (IRs) have been intricately linked to the pathogenesis and treatment outcomes of the breast carcinoma. Studies have revealed that upregulated expression of IRs in breast cancer p...

Full description

Bibliographic Details
Main Authors: Prateek Sharma, Sanjeev Kumar
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2018-01-01
Series:Indian Journal of Medical Research
Subjects:
Online Access:http://www.ijmr.org.in/article.asp?issn=0971-5916;year=2018;volume=147;issue=6;spage=545;epage=551;aulast=Sharma
id doaj-7502c4e50aa74ef8b52e8815f2eb27cf
record_format Article
spelling doaj-7502c4e50aa74ef8b52e8815f2eb27cf2020-11-24T22:40:08ZengWolters Kluwer Medknow PublicationsIndian Journal of Medical Research0971-59162018-01-01147654555110.4103/ijmr.IJMR_403_17S961, a biosynthetic insulin receptor antagonist, downregulates insulin receptor expression & suppresses the growth of breast cancer cellsPrateek SharmaSanjeev KumarBackground & objectives: Insulin resistance associated with hyperinsulinaemia and overexpression of insulin receptors (IRs) have been intricately linked to the pathogenesis and treatment outcomes of the breast carcinoma. Studies have revealed that upregulated expression of IRs in breast cancer pathogenesis regulates several aspects of the malignant phenotype, including cell proliferation and metastasis. This study was aimed to investigate the pivotal role of an IR antagonist S961 on IR signalling and other biological parameters in MCF-7, MDA-MB-231 and T47D cell lines. Methods: The effect of human insulin and S961 on growth, proliferation rate and clonogenic potential of breast cancer cells was evaluated by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide] assay and clonogenic assay. The mRNA expression of IR isoforms (IR-A and IR-B) was measured in the breast carcinoma cells using quantitative PCR. Results: The study revealed that breast cancer cells predominantly expressed IR-A isoform and showed extensive growth and proliferation owing to IR overexpression. It was found that S961 downregulated the IRs (IR-A and IR-B) with nanomolar dose and efficiently blocked expression of IRs even in the presence of insulin. IR mRNA expression levels were significantly downregulated in the continued presence of S961. S961 also inhibited cellular proliferation and colony formation in breast tumour cells. Interpretation & conclusions: IR antagonist, S961 showed distinct antagonism in vitro and appeared to be a powerful therapeutic modality that might provide insight into the pathogenesis of impaired IR signalling.http://www.ijmr.org.in/article.asp?issn=0971-5916;year=2018;volume=147;issue=6;spage=545;epage=551;aulast=SharmaBreast cancer - hyperinsulinaemia - insulin receptor - S961
collection DOAJ
language English
format Article
sources DOAJ
author Prateek Sharma
Sanjeev Kumar
spellingShingle Prateek Sharma
Sanjeev Kumar
S961, a biosynthetic insulin receptor antagonist, downregulates insulin receptor expression & suppresses the growth of breast cancer cells
Indian Journal of Medical Research
Breast cancer - hyperinsulinaemia - insulin receptor - S961
author_facet Prateek Sharma
Sanjeev Kumar
author_sort Prateek Sharma
title S961, a biosynthetic insulin receptor antagonist, downregulates insulin receptor expression & suppresses the growth of breast cancer cells
title_short S961, a biosynthetic insulin receptor antagonist, downregulates insulin receptor expression & suppresses the growth of breast cancer cells
title_full S961, a biosynthetic insulin receptor antagonist, downregulates insulin receptor expression & suppresses the growth of breast cancer cells
title_fullStr S961, a biosynthetic insulin receptor antagonist, downregulates insulin receptor expression & suppresses the growth of breast cancer cells
title_full_unstemmed S961, a biosynthetic insulin receptor antagonist, downregulates insulin receptor expression & suppresses the growth of breast cancer cells
title_sort s961, a biosynthetic insulin receptor antagonist, downregulates insulin receptor expression & suppresses the growth of breast cancer cells
publisher Wolters Kluwer Medknow Publications
series Indian Journal of Medical Research
issn 0971-5916
publishDate 2018-01-01
description Background & objectives: Insulin resistance associated with hyperinsulinaemia and overexpression of insulin receptors (IRs) have been intricately linked to the pathogenesis and treatment outcomes of the breast carcinoma. Studies have revealed that upregulated expression of IRs in breast cancer pathogenesis regulates several aspects of the malignant phenotype, including cell proliferation and metastasis. This study was aimed to investigate the pivotal role of an IR antagonist S961 on IR signalling and other biological parameters in MCF-7, MDA-MB-231 and T47D cell lines. Methods: The effect of human insulin and S961 on growth, proliferation rate and clonogenic potential of breast cancer cells was evaluated by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide] assay and clonogenic assay. The mRNA expression of IR isoforms (IR-A and IR-B) was measured in the breast carcinoma cells using quantitative PCR. Results: The study revealed that breast cancer cells predominantly expressed IR-A isoform and showed extensive growth and proliferation owing to IR overexpression. It was found that S961 downregulated the IRs (IR-A and IR-B) with nanomolar dose and efficiently blocked expression of IRs even in the presence of insulin. IR mRNA expression levels were significantly downregulated in the continued presence of S961. S961 also inhibited cellular proliferation and colony formation in breast tumour cells. Interpretation & conclusions: IR antagonist, S961 showed distinct antagonism in vitro and appeared to be a powerful therapeutic modality that might provide insight into the pathogenesis of impaired IR signalling.
topic Breast cancer - hyperinsulinaemia - insulin receptor - S961
url http://www.ijmr.org.in/article.asp?issn=0971-5916;year=2018;volume=147;issue=6;spage=545;epage=551;aulast=Sharma
work_keys_str_mv AT prateeksharma s961abiosyntheticinsulinreceptorantagonistdownregulatesinsulinreceptorexpressionsuppressesthegrowthofbreastcancercells
AT sanjeevkumar s961abiosyntheticinsulinreceptorantagonistdownregulatesinsulinreceptorexpressionsuppressesthegrowthofbreastcancercells
_version_ 1725705796507926528